StemCyte International, Ltd. (TPEX:4178)

Market Cap	6.24B
Revenue (ttm)	385.12M
Net Income (ttm)	-187.63M
Shares Out	192.24M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	452,561
Average Volume	447,312
Open	31.80
Previous Close	31.80
Day's Range	31.80 - 33.00
52-Week Range	20.50 - 40.45
Beta	n/a
RSI	63.59
Earnings Date	Apr 29, 2026

About StemCyte International

StemCyte International, Ltd., together with its subsidiaries, operates cord blood cell banks in the United States and Taiwan. The company offers public donation umbilical cord blood transplantation and private umbilical cord blood storage services; and cell products and services. It also engages in the research and development of biotechnology and cell-based new drugs; and supply of cellular materials. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological ...

• Industry: Miscellaneous Health And Allied Services, Not Elsewhere Classified
• Founded: 1997
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4178

Financial Performance

In 2024, StemCyte International's revenue was 382.69 million, an increase of 5.49% compared to the previous year's 362.78 million. Losses were -205.66 million, -35.68% less than in 2023.